Tikva Allocell

Tikva Allocell is a Singapore-based late-preclinical-stage cell therapy company developing allogeneic, off-the-shelf T cell therapies for solid tumors. Founded in 2023, the company's platform centers on a second-generation Allogeneic EBV-Specific T cell (ALLO EBVST) technology, which leverages donor-derived EBV-specific T cells enhanced with SerpinB9 (CAS) and engineered with a B7-H3 chimeric antigen receptor to overcome host immune rejection and persist long enough to attack solid tumors. Its lead program, TAVST01, targets B7-H3-positive cancers including lung, breast, prostate, pancreatic, and pediatric cancers. The company raised $8 million in Series A financing in July 2026, led by Kantharos Capital, to complete IND-enabling studies and initiate Phase 1 clinical trials in Singapore and the United States.